Search

Canadian funding of proteomic and genomic research will be provided to research institutes, companies, universities and government laboratories throughout the country.

First there was the Human Genome Project. Now comes proteomics, figuring out how proteins work. Will Caprion Pharmaceuticals play a big role in the biotech quest? No one can accuse [...]

The Canadian biotechnology industry is rapidly growing, with the recent release of Statistics Canada's industry survey stating that 360 biotech companies were formed in Canada in 1999, compared to 280 in 1997. The survey also stated that Canadian biotech companies spent C$832 million in research and development (R&D) in 1999, with an expected C$1.5 billion to be spent on R&D in 2002. This article covers companies involved in proteomics, stem cell research, and plant-based bioproduction.

Toronto is that quintessentially Canuck phenomenon--full of accomplishments that go comparatively unnoticed. The fifth-largest city in North America, it's Canada's financial and corporate headquarters, and seat of the world's seventh-biggest [...]

The product development operations of various Canadian biotechnology companies are discussed.

The establishment of StemPath and the product development of Canadian biotechnology companies are discussed.

As the U.S. decides to fund stem cell research for exisiting cell lines only, Canadian biotechnology companies may have to address change regarding issues of licensing. Developments at Aegera Therapeutics Inc., GlycoDesign Inc., Gemin X Biotechnologies Inc., SignalGene Inc., Cangene Corp., SkyePharma PLC, QLT Inc., Cardiome Pharmaceuticals Inc., and Hemosol Inc. are discussed.

Xenon Genetics Inc.'s focus is on clinically oriented genomics technology for drug discovery. The article details how the company's strategy encourages probability of identifying disease-causing genes and furthers its current research partnerships.

Synsorb Biotech Inc. of Calgary, Alberta, has sped up its Phase III trials for Synsorb Cd, indicated for the treatment of recurrent Clostridium difficle-related diarrhea. According to David Cox, president and CEO, the aim is to file an NDA by the latter part of 2002 or early 2003. In accelerating these trials, the company has also decided to discontinue Synsorb PK development.

MWG-Biotech AG is implementing strategies to obtain 50% of the American Genomic products and services market within two years. Bioinformatics platform development, production plans for functionally validated DNA arrays, sequencing and bioinformatics capability investment, oligonucleotide manufacturing capacity goals, and efforts to commercialize HPSE arrays are discussed.

Many companies presented partnerships, product developments, and financial statements at BioContact, the annual Canadian bioindustry conference. MDS Proteomics Inc. may announce an initial public offering soon, and StressGen Biotechnologies Corp. is arranging funding for development of a new cancer treatment. Other companies and conference topics are also discussed.

Is your company headed for the financial abyss? Better call Sam Fleiser, turnaround guy Sam Fleiser knows what it takes to make a successful company--or at least he knows what [...]

ProMetic's Pierre Laurin wants to put protein in your portfolio A couple of autumns ago, Pierre Laurin sat in an exclusive Toronto club across the breakfast table from the vice-chairman [...]

A glimpse of the 2001 CIC Medal winner, Geoffrey Ozin. No one could accuse Geoffrey Ozin, FCIC, of thinking too big. In fact, you might say Ozin's research into materials [...]

Angiotech races for the finish line Analyst reaction to the latest news from Angiotech Pharmaceuticals Inc. was unequivocal. 'There's no way to sugarcoat it: they missed their numbers,' says Archie [...]

Cancer-fighting Biomira is looking to get healthy Take a quick peek at the scorecard for TSE block trading on May 3, tucked into a corner of a newspaper's business section [...]

THINK OF THE MONEY YOU'D HAVE MADE BY BUYING shares in an obscure little biotech outfit called Quadra Logic Technologies Inc., say, at the end of 1991. Stock for the [...]

We asked a leading industry insider which companies to watch in a volatile sector. Some might give your portfolio a shot in the arm. Others could leave you feeling queasy [...]

These survivors are back in the black with a wireless camera Picture the OJ Simpson chopper chase, Donovan Bailey's 100-metre win, the San Francisco earthquake, Di Caprio and Winslet at [...]

The way many Newfoundlanders see it, outsiders have plundered their province's natural resources for far too long. Fish, timber, hydro power, oil, minerals--the list keeps getting longer, spurring local efforts [...]